Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with...

Area of Science:

• Oncology
• Immunology
• Pharmacovigilance

Background:

• Malignant melanoma incidence is rising globally.
• Immune checkpoint inhibitors (ICIs) improve advanced melanoma survival but risk severe immune-related adverse events (irAEs).
• Predicting irAEs is crucial for patient safety.

Purpose of the Study:

• To investigate if patient baseline characteristics predict severe gastrointestinal, hepatic, and pulmonary irAEs.
• To analyze irAE predictors in patients receiving ipilimumab (anti-CTLA-4) and/or nivolumab/pembrolizumab (anti-PD-1).

Main Methods:

• Systematic literature search in Ovid MEDLINE and EMBASE following PRISMA guidelines.
• Included 13 studies from 1694 articles, analyzing 22 treatment arms and 3 treatment groups (anti-CTLA-4, anti-PD-1, combination).
• Descriptive analysis of patient baseline characteristics (age, gender, performance status) and severe irAEs (colitis, hepatitis, pneumonitis).

Main Results:

• Data limitations prevented direct comparison of individual baseline characteristics and specific irAE associations.
• Descriptive analysis showed no significant association between median age, gender distribution, or performance status and severe colitis, hepatitis, or pneumonitis across treatment groups.
• No significant predictive value identified for common baseline characteristics.

Conclusions:

• Current data reporting hinders the identification of patient baseline characteristics that predict severe irAEs.
• Greater transparency and standardization in reporting patient-specific irAE data are urgently needed.
• Further research with standardized reporting is required to improve irAE prediction in melanoma patients treated with ICIs.